BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
17.99
+0.17 (0.95%)
May 8, 2026, 4:00 PM EDT - Market closed
BioAge Labs Revenue
BioAge Labs had revenue of $2.77M in the quarter ending March 31, 2026, with 91.04% growth. This brings the company's revenue in the last twelve months to $10.32M, up 610.96% year-over-year. In the year 2025, BioAge Labs had annual revenue of $9.00M.
Revenue (ttm)
$10.32M
Revenue Growth
+610.96%
P/S Ratio
77.43
Revenue / Employee
$166,387
Employees
62
Market Cap
798.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBIOA News
- 1 day ago - BioAge Labs Transcript: Status update - Transcripts
- 1 day ago - BioAge Labs reports Q1 EPS (52c), consensus (63c) - TheFly
- 1 day ago - BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 days ago - BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - GlobeNewsWire
- 18 days ago - BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2 - TheFly
- 18 days ago - BioAge Labs Transcript: Study result - Transcripts
- 18 days ago - BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP - GlobeNewsWire
- 23 days ago - BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts